A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD
J Vestbo, L Tan, G Atkinson… - European Respiratory …, 2009 - Eur Respiratory Soc
Anti-inflammatory drugs are lacking in chronic obstructive pulmonary disease (COPD) and
inhibitors of the phosphodiesterase type-4 (PDE4) enzyme have been suggested to be an …
inhibitors of the phosphodiesterase type-4 (PDE4) enzyme have been suggested to be an …
Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment
GP Currie, CA Butler, WJ Anderson… - British journal of …, 2008 - Wiley Online Library
Chronic obstructive pulmonary disease represents a major global health care burden for
both primary and secondary care providers and is the most common respiratory condition …
both primary and secondary care providers and is the most common respiratory condition …
Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases
V Lagente, C Martin-Chouly, E Boichot… - Memórias do Instituto …, 2005 - SciELO Brasil
Phosphodiesterases (PDEs) are responsible for the breakdown of intracellular cyclic
nucleotides, from which PDE4 are the major cyclic AMP metabolizing isoenzymes found in …
nucleotides, from which PDE4 are the major cyclic AMP metabolizing isoenzymes found in …
Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease
KF Rabe - British journal of pharmacology, 2011 - Wiley Online Library
Phosphodiesterase 4 (PDE4) is a member of the PDE enzyme superfamily that inactivates
cyclic adenosine monophosphate and cyclic guanosine monophosphate, and is the main …
cyclic adenosine monophosphate and cyclic guanosine monophosphate, and is the main …
Phosphodiesterase inhibitors in airways disease
KF Chung - European journal of pharmacology, 2006 - Elsevier
Phosphodiesterases hydrolyse intracellular cyclic nucleotides, cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into inactive 5 …
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into inactive 5 …
Discovery and optimization of thiazolidinyl and pyrrolidinyl derivatives as inhaled PDE4 inhibitors for respiratory diseases
L Carzaniga, G Amari, A Rizzi, C Capaldi… - Journal of Medicinal …, 2017 - ACS Publications
Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing enzyme involved in the
pathogenesis of inflammatory disease, and its pharmacological inhibition has been shown …
pathogenesis of inflammatory disease, and its pharmacological inhibition has been shown …
Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease
CP Page - International archives of allergy and immunology, 2015 - karger.com
Xanthines like theophylline have long been recognised as being effective drugs for the
treatment of asthma and chronic obstructive pulmonary disease (COPD). They are of interest …
treatment of asthma and chronic obstructive pulmonary disease (COPD). They are of interest …
2 PDE4 inhibitors–a review of the current field
NJ Press, KH Banner - Progress in medicinal chemistry, 2009 - Elsevier
Publisher Summary This chapter focuses on phosphodiesterase-4 (PDE4) enzyme inhibitors
and their potential therapeutic utility. The chapter presents the in vitro pharmacology of …
and their potential therapeutic utility. The chapter presents the in vitro pharmacology of …
[HTML][HTML] Phosphodiesterases as therapeutic targets for respiratory diseases
H Zuo, I Cattani-Cavalieri, N Musheshe… - Pharmacology & …, 2019 - Elsevier
Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and
asthma, affect millions of people all over the world. Cyclic adenosine monophosphate …
asthma, affect millions of people all over the world. Cyclic adenosine monophosphate …
Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice
S Udalov, R Dumitrascu, SS Pullamsetti… - BMC Pulmonary …, 2010 - Springer
Background Pulmonary fibrosis (PF) is a group of devastating and largely irreversible
diseases. Phosphodiesterase (PDE) 4 is involved in the processes of remodeling and …
diseases. Phosphodiesterase (PDE) 4 is involved in the processes of remodeling and …